WuXi Biologics serves up $1.4B expansion of research and manufacturing center in Singapore
While WuXi Biologics is continuing to work with US regulators on inspections of its facilities, the company is also looking to expand one of its manufacturing sites in Asia.
On Tuesday, the company announced that it will expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore. The expansion includes a 10-year, $1.4 billion (S$2 billion) investment plan from the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.